In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes two weeks after J&J ...

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

Trump's pick for HHS secretary who endured confirmation hearings last week—has repeatedly criticized industry ties to the FDA ...

Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...